Hormonal contraception in HIV-positive women

AIDS Reader

Volumn 18, Issue 7, 2008, Pages

  Womack, Julie ^a   Williams, Ann ^b  

^a Vet Admin Coop Studies Group   (United States)

^b YALE UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

HIV AIDS; Hormonal contraception; Mother to child transmission; Prevention

Indexed keywords

ANTIRETROVIRUS AGENT; DESOGESTREL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; GESTODENE; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEDROXYPROGESTERONE ACETATE; NORELGESTROMIN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BONE METABOLISM; DYSLIPIDEMIA; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INSULIN RESISTANCE; METABOLIC DISORDER; OSTEOPENIA; OSTEOPOROSIS; PREGNANCY; RISK ASSESSMENT; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADULT; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS;

EID: 47249091908     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Branson BM, Handsfield HH, Lampe MA, et al; Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17; quiz CE1-CE4.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance in Adolescents and Young Adults (through 2005). Slide Set. June 2007.
3. Hatcher RA, Trussell J, Stewart FH, et al, eds. Contraceptive Technology. 18th rev ed. New York: Ardent Media, Inc; 2004.
4. Cejtin HE, Jacobson L, Springer G, et al. Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS. 2003;17:1702-1704.
5. Clark RA, Theall KP. Trends and correlates of hormonal contraception use among HIV-infected women. J Acquir Immune Defic Syndr. 2004;36:986-988.
6. Wilson TE, Massad LS, Riester KA, et al. Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: results from the Women's Interagency HIV Study. AIDS. 1999;13:591-598.
7. Massad LS, Evans CT, Wilson TE, et al. Contraceptive use among U.S. women with HIV. J Womens Health (Larchmt). 2007;16:657-666.
8. World Contraceptive Use. http://www.un.org/esa/population/publications/ contraceptive2005/WCU2005.htm. Accessed March 3, 2007.
9. Blair JM, Hanson DL, Jones JL, Dworkin MS. Trends in pregnancy rates among women with human immunodeficiency virus. Obstet Gynecol. 2004;103:663-668.
10. Morrison CS, Cates W Jr. Preventing unintended pregnancy and HIV transmission: dual protection or dual dilemma? Sex Transm Dis. 2007;34:873-875.
11. Wang CC, McClelland RS, Overbaugh J, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS. 2004;18:205-209.
12. Clark RA, Theall KP, Amedee AM, et al. Lack of association between genital tract HIV-1 RNA shedding and hormonal contraceptive use in a cohort of Louisiana women. Sex Transm Dis. 2007;34:870-872.
13. Cejtin HE. Gynecologic issues in the HIV-infected woman. Obstet Gynecol Clin North Am. 2003;30:711-729.
14. Tai JH, Udoji MA, Barkanic G, et al. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis. 2007;496:1044-1052.
15. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther. 2007;81:222-227.
16. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16:263-272.
17. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception. 1994;50(6 suppl 1):S1-S195.
18. de Maat MM, Ekhart GC, Huitema AD, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet. 2003;42:223-282.
19. Panel oAGfAaA. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed April 4, 2008.
20. Delvaux T, Nöstlinger C. Reproductive choice for women and men living with HIV: contraception, abortion and fertility. Reprod Health Matters. 2007;15(29 suppl):46-66.
21. Watts DH, Park JG, Cohn SE, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception. 2008;77:84-90.
22. Mitchell HS, Stephens E. Contraception choice for HIV positive women. Sex Transm Infect. 2004;80:167-173.
23. le Roux CW, Beckles MA, Besser GM, et al. Cushing's syndrome secondary to inhaled corticosteroids mimicking HIV-associated lipodystrophy. HIV Med. 2001;2:133-135.
24. Chu JH, Gange SJ, Anastos K, et al. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol. 2005;161:881-890.
25. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
26. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs. 2003;63:2555-2574.
27. Friis-Møller N, Weber R, Reiss P, et al; DAD Study Group. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
28. Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. J Intern Med Suppl. 1996;738:1-60.
29. Grunfeld C, Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis. 2003;37(suppl 2):S43-S46.
30. Kotler D. Challenges to diagnosis of HIV-associated wasting. J Acquir Immune Defic Syndr. 2004;37(suppl 5):S280-S283.
31. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000;31:1467-1475.
32. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;16(5):F1-F8.
33. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991;90:154-162.
34. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36(suppl 2):S101-S105.
35. McComsey G, Huang J, Woolley I, et al. Fragility fractures in HIV-infected subjects, an area for improvement. 11th Conference on retroviruses and opportunistic infections; February 8-11, 2004; San Francisco.
36. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004;19:402-409.
37. Godsland IF. Oestrogens and insulin secretion. Diabetologia. 2005;48:2213-2220.
38. Kahn HS, Curtis KM, Marchbanks PA. Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care. 2003;26:216-225.
39. Gaspard U, Scheen A, Endrikat J, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception. 2003;67:423-429.
40. Spellacy WN. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives. Am J Obstet Gynecol. 1982;142(6, pt 2):732-734.
41. Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA. 1998;280:533-538.
42. Ludicke F, Gaspard UJ, Demeyer F, et al. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception. 2002;66:411-415.
43. Godsland IF, Crook D. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol. 1994;170(5, pt 2):1528-1536.
44. Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond). 2002;102:151-166.
45. Garza-Flores J, De la Cruz DL, Valles de Bourges V, et al. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception. 1991;44:61-71.
46. Knopp RH, LaRosa JC, Burkman RT Jr. Contraception and dyslipidemia. Am J Obstet Gynecol. 1993;168(6, pt 2):1994-2005.
47. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209-2216.
48. Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception. 1998;57:231-235.
49. Bahamondes L, Juliato CT, Villarreal M, et al. Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives. Contraception. 2006;74:259-263.
50. Cobb KL, Kelsey JL, Sidney S, et al. Oral contraceptives and bone mineral density in white and black women in CARDIA. Coronary Risk Development in Young Adults. Osteoporos Int. 2002;13:893-900.
51. FDA. Physician Information. http://www.fda.gov/medwatch/SAFETY/2004/ DepoProvera_Label.pdf. Accessed April 9, 2007.
52. Kaunitz AM. Depo-Provera's black box: time to reconsider? Contraception. 2005;72:165-167
53. Cundy T, Cornish J, Roberts H, Reid IR. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol. 2002;186:978-983.
54. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004;17:17-21.
55. Kim C, Seidel KW, Begier EA, Kwok YS. Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med. 2001;161:1766-1771.